Construction of the production facilities of the XENOGP enterprise (Q104245): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The company XenoGP plans to create a production line along with the quality control unit thanks to the funding obtained from the project. The production laboratory shall be created by a spin off type. The investment will serve to implement the market of research carried out in the scientific bodies and directly by the scientific staff of the units: PDR n. Sebastian Radu, Dr. Paulina Wdovicak. A engineered bonding technology for the modified dr...) |
(Created claim: summary (P836): XenoGP plans to create a production line together with the quality control department with the co-financing obtained from the presented project. The production laboratory is created by a spin-out company. The investment will serve the market implementation of research carried out in scientific units and directly by researchers of entities: PDR n. med. Sebastian Radej and dr n. med. I'm Paulina Widowak. Developed technology of combining textile m...) |
||||||||||||||
| Property / summary | |||||||||||||||
XenoGP plans to create a production line together with the quality control department with the co-financing obtained from the presented project. The production laboratory is created by a spin-out company. The investment will serve the market implementation of research carried out in scientific units and directly by researchers of entities: PDR n. med. Sebastian Radej and dr n. med. I'm Paulina Widowak. Developed technology of combining textile material restraining modified dressing of tissue material at the site of damage to the patient’s skin, allowing for free exchange of textile material without compromising the interaction between the modified dressing and the damaged skin of the patient. properly modified tissue material derived from pig retains the natural properties of the skin, replacing damaged human tissue until the patient produces its own cells. At the same time, when the skin is reconstituted, it affects the dressing so that it is spontaneously separated, thereby reducing the possibility of damaging the patient’s delicate layer of regenerated skin, often occurring when changing dressings appropriate to date. The objectives of the project are to support 1 spin-out companies, the introduction of 1 product innovations (on a global scale) based on research (research implementation). As a result of the project, 2 new specialised workplaces will be created. (English) | |||||||||||||||
| Property / summary: XenoGP plans to create a production line together with the quality control department with the co-financing obtained from the presented project. The production laboratory is created by a spin-out company. The investment will serve the market implementation of research carried out in scientific units and directly by researchers of entities: PDR n. med. Sebastian Radej and dr n. med. I'm Paulina Widowak. Developed technology of combining textile material restraining modified dressing of tissue material at the site of damage to the patient’s skin, allowing for free exchange of textile material without compromising the interaction between the modified dressing and the damaged skin of the patient. properly modified tissue material derived from pig retains the natural properties of the skin, replacing damaged human tissue until the patient produces its own cells. At the same time, when the skin is reconstituted, it affects the dressing so that it is spontaneously separated, thereby reducing the possibility of damaging the patient’s delicate layer of regenerated skin, often occurring when changing dressings appropriate to date. The objectives of the project are to support 1 spin-out companies, the introduction of 1 product innovations (on a global scale) based on research (research implementation). As a result of the project, 2 new specialised workplaces will be created. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: XenoGP plans to create a production line together with the quality control department with the co-financing obtained from the presented project. The production laboratory is created by a spin-out company. The investment will serve the market implementation of research carried out in scientific units and directly by researchers of entities: PDR n. med. Sebastian Radej and dr n. med. I'm Paulina Widowak. Developed technology of combining textile material restraining modified dressing of tissue material at the site of damage to the patient’s skin, allowing for free exchange of textile material without compromising the interaction between the modified dressing and the damaged skin of the patient. properly modified tissue material derived from pig retains the natural properties of the skin, replacing damaged human tissue until the patient produces its own cells. At the same time, when the skin is reconstituted, it affects the dressing so that it is spontaneously separated, thereby reducing the possibility of damaging the patient’s delicate layer of regenerated skin, often occurring when changing dressings appropriate to date. The objectives of the project are to support 1 spin-out companies, the introduction of 1 product innovations (on a global scale) based on research (research implementation). As a result of the project, 2 new specialised workplaces will be created. (English) / qualifier | |||||||||||||||
point in time: 17 October 2020
| |||||||||||||||
Revision as of 16:44, 17 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Construction of the production facilities of the XENOGP enterprise |
Project in Poland financed by DG Regio |
Statements
999,810.0 zloty
0 references
1,428,300.0 zloty
0 references
70.0 percent
0 references
1 September 2017
0 references
30 September 2018
0 references
XENOGP SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
0 references
Spółka XenoGP planuje dzięki dofinansowaniu uzyskanemu z przedstawionego projektu stworzyć linię produkcyjną wraz z działem kontroli jakości,. Laboratorium produkcyjne tworzone jest przez przedsiębiorstwo odpryskowe typu spin-out. Inwestycja będzie służyła wdrożeniu rynkowemu badań realizowanych w jednostkach naukowych oraz bezpośrednio prze pracowników naukowych jednostek: pdr n. med. Sebastian Radej i dr n. med. Paulina Wdowiak. Opracowana technologii łącznia materiału tekstylnego przytrzymującego modyfikowany opatrunek z materiału tkankowego w miejscu uszkodzenia skóry pacjenta, pozwalający na swobodną wymianę materiału tekstylnego bez naruszenia oddziaływań pomiędzy modyfikowanym opatrunkiem a uszkodzoną skórą pacjenta. odpowiednio zmodyfikowany materiał tkankowy pochodzący od świni zachowuje naturalne właściwości skóry zastępując uszkodzoną tkankę ludzką do czasu wytworzenia przez pacjenta własnych komórek. Jednocześnie z chwilą odtworzenia prawidłowej skóry oddziałuje ona tak na opatrunek że ulega on spontanicznemu odseparowaniu redukując tym samym możliwość uszkodzenia delikatnej warstwy zregenerowanej skóry pacjenta , często występującej podczas zmiany opatrunków stosownych dotychczas. Cele projektu jest wsparcie 1 przedsiębiorstwa typu spin-out, wprowadzenie 1 innowacji produktowej (w skali światowej) bazującej na badaniach naukowych (wdrożenie badań naukowych). W wyniku realizacji projektu powstaną 2 nowe specjalistyczne miejsca pracy. (Polish)
0 references
XenoGP plans to create a production line together with the quality control department with the co-financing obtained from the presented project. The production laboratory is created by a spin-out company. The investment will serve the market implementation of research carried out in scientific units and directly by researchers of entities: PDR n. med. Sebastian Radej and dr n. med. I'm Paulina Widowak. Developed technology of combining textile material restraining modified dressing of tissue material at the site of damage to the patient’s skin, allowing for free exchange of textile material without compromising the interaction between the modified dressing and the damaged skin of the patient. properly modified tissue material derived from pig retains the natural properties of the skin, replacing damaged human tissue until the patient produces its own cells. At the same time, when the skin is reconstituted, it affects the dressing so that it is spontaneously separated, thereby reducing the possibility of damaging the patient’s delicate layer of regenerated skin, often occurring when changing dressings appropriate to date. The objectives of the project are to support 1 spin-out companies, the introduction of 1 product innovations (on a global scale) based on research (research implementation). As a result of the project, 2 new specialised workplaces will be created. (English)
17 October 2020
0 references
Identifiers
RPLU.03.03.00-06-0001/17
0 references